Trial Profile
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HIGH DOSE MHAA4549A IN HEALTHY VOLUNTEERS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2017
Price :
$35
*
At a glance
- Drugs Gedivumab (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Genentech
- 05 Jul 2016 Results published in the Antimicrobial Agents and Chemotherapy
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 22 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.